The birth and postnatal development of purinergic signalling

Burnstock, Geoffrey; Fredholm, Bertil B.; North, Richard; Verkhratsky, Alexei

doi:10.1111/j.1748-1716.2010.02114.x

Cited by 125 publications

(126 citation statements)

References 912 publications

(874 reference statements)

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…This receptor family comprises two different classes of membrane proteins named P2Y and P2X receptors, which are distinguished on the base of their structure and function. To date, eight subtypes of the P2Y receptors, belonging to the family of G protein coupled receptors (GPCRs), and seven subtypes (P2X1-7) of the P2X ion channels, permeable to Na + , K + , Ca ++ ions and small molecules, have been cloned from humans [1][2][3][4][5]. P2X receptors assemble as homo-or heterotrimers [6,7] and share a common structure, presenting intracellular N-and C-termini, two transmembrane domains (TM1 and TM2) and a large glycosylated and cysteine-rich extracellular domain [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents

Ben

Marchenkova

Thomas

et al. 2016

Purinergic Signalling

View full text Add to dashboard Cite

Blocking membrane currents evoked by the activation of purinergic P2X3 receptors localized on nociceptive neurons represents a promising strategy for the development of agents useful for the treatment of chronic pain conditions. Among compounds endowed with such antagonistic action, 2′,3′-O-(2,4,6-trinitrophenyl)-ATP (TNP-ATP) is an ATP analogue, whose inhibitory activity on P2X receptors has been previously reported. Based on the results of molecular modelling studies performed with homology models of the P2X3 receptor, novel adenosine nucleotide analogues bearing cycloalkyl or arylalkyl substituents replacing the trinitrophenyl moiety of TNP-ATP were designed and synthesized. These new compounds were functionally evaluated on native P2X3 receptors from mouse trigeminal ganglion (TG) sensory neurons using patch clamp recordings under voltage clamp configuration. Our data show that some of these molecules are potent (nanomolar range) and reversible inhibitors of P2X3 receptors, without any apparent effect on trigeminal GABA A and 5-HT 3 receptors, whose membrane currents were unaffected by the tested compounds.

show abstract

Section: Introductionmentioning

confidence: 99%

2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents

Ben

Marchenkova

Thomas

et al. 2016

Purinergic Signalling

View full text Add to dashboard Cite

show abstract

“…Extracellular effects of purines were identified also in non-cardiovascular preparations in the years from 1932 to 1954 [2]. First indication that ATP might act as neurotransmitter in the peripheral nervous system was obtained by Holton and Holton in 1954 [3].…”

Section: The History Of How the Congresses Of Purines Have Grown Up Omentioning

confidence: 99%

From the 7th Joint Italian-German Purine Club Meeting to European Purine Club Meetings

Pedata

2017

Purinergic Signalling

View full text Add to dashboard Cite

“…Purinergic receptors are expressed in many mammalian cell types and are activated by extracellular adenine and uridine nucleotides or nucleosides [6,[29][30][31]. Both P1 receptors for adenosine and P2 receptors (P2Rs) for adenine and/or uridine nucleotides are expressed in cells comprising the CNS and have been shown to regulate important physiological and pathophysiological functions, including neurotransmission, inflammation, cell growth, and apoptosis [11,[31][32][33].…”

Section: P2 Receptors In the Cnsmentioning

confidence: 99%